SCHEMBL694118

SCHEMBL694118

Cc1cc(N2C[C@H](S(=O)(=O)CC3CC3)C[C@H]2C(=O)O)n(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 4/20 0.39
NOTUM Q6P988 1/20 0.36
PHGDH O43175 1/20 0.36
CTSS P25774 3/20 0.34
CTSL P07711 2/20 0.34
CTSB P07858 2/20 0.34
CTSK P43235 2/20 0.34
MDM2 Q00987 1/20 0.33
NPY5R Q15761 1/20 0.33
CHRNA7 P36544 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
EPHX2 P34913 1/20 0.33
S1PR1 P21453 1/20 0.33
MGAT2 Q10469 1/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
PTGER4 P35408 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15327758 1.00 CRHR1 (0.39) CRHR1NOTUMPHGDHCTSSCTSL
SCHEMBL694463 0.91 CRHR1 (0.39) CRHR1CTSSCTSLCTSBCTSK
SCHEMBL2105671 0.91 CRHR1 (0.39) CRHR1CTSSCTSLCTSBCTSK
SCHEMBL695239 0.87 NOTUM (0.38) CRHR1NOTUMPHGDHCTSSCTSL
SCHEMBL696306 0.85 CTSS (0.49) CTSS
SCHEMBL695506 0.84 ELOVL6 (0.43) NOTUMCTSSCTSLCTSBCTSK
SCHEMBL15327102 0.82 SMO (0.36)
SCHEMBL696581 0.82 SMO (0.36)
SCHEMBL696580 0.82 SMO (0.36)
SCHEMBL696030 0.82 CTSS (0.45) CRHR1CTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CRHR1 57/4885NOTUM 2571/4885PHGDH 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.